ArticleAntimicrobial agents and chemotherapy2020
Second-Generation Antidiabetic Sulfonylureas Inhibit Candida albicans and Candidalysin-Mediated Activation of the NLRP3 Inflammasome.
Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Immune Consequences of Metabolic Syndrome and Its Treatment: A Cytokine Perspective.Immunology · 2026Article
- Phenotypic and genotypic analysis ofInfection and immunity · 2026Article
- An In Vitro A-431 Epithelial Cell Infection Model for Studying Fungal Pathogenicity and Immune Responses Associated With Vulvovaginal Candidiasis.Bio-protocol · 2026Article
- Candidalysin at the epithelial-systemic interface: mechanistic evidence, critical-care relevance, and translational opportunities in invasive candidiasis.Frontiers in cellular and infection microbiology · 2026Review
- Sulphonylureas as Adjunct Therapeutic Agents in the Treatment of Autoimmune Conditions: A Narrative Review.Pharmacology research & perspectives · 2025Review
- NLRP3 Inflammasome in Gynecologic Inflammatory Diseases: Mechanisms, Pathophysiology, and Therapeutic Strategies.Journal of inflammation research · 2025Review
- New Insights on NLRP3 Inflammasome: Mechanisms of Activation, Inhibition, and Epigenetic Regulation.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2024Review
- Macrophage pyroptosis induced by Candida albicans.Pathogens and disease · 2024Review
- The Interplay betweenMicroorganisms · 2023Review
- Pathogenesis and virulence ofVirulence · 2022Review
- Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study.BMJ (Clinical research ed.) · 2022Article
- Rapid Hypothesis Testing in Candida albicans Clinical Isolates Using a Cloning-Free, Modular, and Recyclable System for CRISPR-Cas9 Mediated Mutant and Revertant Construction.Microbiology spectrum · 2022Article
- Anti-diabetics and antimicrobials: Harmony of mutual interplay.World journal of diabetes · 2021Review
- A variant ECE1 allele contributes to reduced pathogenicity of Candida albicans during vulvovaginal candidiasis.PLoS pathogens · 2021Article
- Identification of Dual-Target Compounds with Antifungal and Anti-NLRP3 Inflammasome Activity.ACS infectious diseases · 2021Article
- Inflammasomes in Teleosts: Structures and Mechanisms That Induce Pyroptosis during Bacterial Infection.International journal of molecular sciences · 2021Review
- Role of inflammasomes/pyroptosis and PANoptosis during fungal infection.PLoS pathogens · 2021Review
- Some like it hot: Candida activation of inflammasomes.PLoS pathogens · 2020Article
- Review
- Vulvovaginal Candidiasis: A Current Understanding and Burning Questions.Journal of fungi (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Repurposing of currently approved medications is an attractive option for the development of novel treatment strategies against physiological and infectious diseases. The antidiabetic sulfonylurea glyburide has demonstrated off-target capacity to inhibit activation of the NLRP3 inflammasome in a variety of disease models, including vaginal candidiasis, caused primarily by the fungal pathogen
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.